ZEGFROVY

Zegfrovy Warnings and Precautions

• Interstitial lung disease (ILD) / pneumonitis: Can be severe or fatal. Patients should be monitored for new or worsening pulmonary symptoms such as shortness of breath, cough, or fever.
• Gastrointestinal adverse reactions: Diarrhea occurs in the majority of patients (73%) and can be severe; supportive management and dose adjustment may be needed.
• Dermatologic adverse reactions: Rash, dry skin, and related skin reactions are common and may require dose modification in more severe cases.
• Ocular toxicity: Including keratitis, reported in some patients. Prompt evaluation is recommended for new or worsening eye symptoms.
• Embryo-fetal toxicity: Zegfrovy can cause fetal harm. Effective contraception is recommended during treatment and for a period after the last dose.

How to Access Zegfrovy in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Zegfrovy to India?

Zegfrovy (sunvozertinib) tablets may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified doctor
• The patient's diagnostic reports, including confirmation of EGFR exon 20 insertion mutation
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Zegfrovy available in India?

Zegfrovy (sunvozertinib tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Zegfrovy is not commercially marketed in India.

However, patients in India can legally access Zegfrovy through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.

Zegfrovy received accelerated US FDA approval in 2025, ensuring full transparency throughout the process.

Zegfrovy can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

NPP also facilitates access to other targeted therapies for EGFR exon 20 insertion-mutated NSCLC, including Rybrevant (amivantamab), for patients whose treating oncologist considers these options relevant to their case.

Sourcing & Delivery

NamedPatientProgram.com (NPP) can source Zegfrovy from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. Zegfrovy tablets should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and are handled under temperature-controlled shipping conditions throughout transit. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For Zegfrovy cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability of Zegfrovy Across Major Cities in India

Patients across India can access Zegfrovy through regulated import pathways, with delivery arranged to the treating hospital based on a valid oncologist's prescription and confirmed EGFR exon 20 testing.

Mumbai

A major oncology hub with institutions like Tata Memorial, Mumbai coordinates access to advanced lung cancer therapies like Zegfrovy for eligible patients.

Delhi

As part of the Delhi NCR region, the city has a strong concentration of cancer centers, making it a key location for accessing targeted lung cancer treatments.

Bangalore

With a growing network of multispecialty oncology hospitals, Bangalore supports access to Zegfrovy through structured import pathways guided by treating specialists.

Chennai

Home to several reputed cancer treatment centers, Chennai facilitates access to Zegfrovy for patients with EGFR exon 20-mutated NSCLC.

Hyderabad

A growing hub for oncology care, Hyderabad supports coordinated access to Zegfrovy for eligible patients under specialist supervision.

Kolkata

Eastern India's leading cancer centers in Kolkata coordinate Zegfrovy access for patients with advanced lung cancer.

Pune

With an expanding base of oncology clinics, Pune facilitates timely access to Zegfrovy under prescription.

Ahmedabad

Gujarat's leading cancer hospitals support regulated access to Zegfrovy for eligible patients.

Kochi

Kerala's healthcare network, including major cancer centers in Kochi, coordinates access to advanced oral targeted therapies like Zegfrovy.

Chandigarh

Serving North India, Chandigarh's oncology centers facilitate access to Zegfrovy for patients from Punjab, Haryana, and Himachal Pradesh.

Jaipur

Rajasthan's leading hospitals support patient access to Zegfrovy through the Named Patient Program.

Lucknow

A key referral center for North India, Lucknow facilitates coordinated access to Zegfrovy under oncologist care.

Bhubaneswar

Odisha's growing oncology sector supports patient access to Zegfrovy.

Guwahati

As a referral hub for the North-East, Guwahati facilitates access to Zegfrovy for patients across the region.

Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.